Eli Lilly’s early Alzhiemer’s treatment was approved by the Food and Drug Administration on Tuesday, making it the second drug on the U.S. market aimed at slowing progression of the debilitating neurological disease.
The treatment, whose scientific name is donanemab and will be sold under the brand name Kisunla, will compete with Eisai and Biogen’s Leqembi, which got full approval last year.
The clearance of Kisunla comes after several regulatory hurdles. The drug was originally expected to be approved earlier this year, but the FDA convened a panel of advisers to weigh the risks and benefits of the treatment. The committee unanimously backed the treatment in a meeting last month.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.